This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: To study the frequency of different gene mutations in patients with early-onset parkinsonism and bilateral subthalamic nucleus deep brain stimulation (STN-DBS) and the short- and long-term surgical outcome in mutation-positive (MUT+) and -negative (MUT−) patients.
Methods: Eighty patients with disease onset at age ≤ 45 years and bilateral STN-DBS were screened for mutations in the Parkin gene and PINK1 gene and for the recurrent p.G2019S mutation in the LRRK2 gene. The Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr (H-Y) scale were used to compare the on- and off-medication conditions preoperatively and in the off-medication/on-stimulation condition postoperatively.
Results: We identified 12 mutation carriers (11 Parkin [6 with 2 mutated alleles, 5 with 1 mutated allele], 1 homozygous PINK1). There were no clinical differences between the MUT− and MUT+ patients preoperatively, except for more severe H-Y stage and postural and gait scores in the on-medication state in the MUT+ group. During the first year after surgery, MUT− patients showed better clinical improvement (56% motor UPDRS improvement) compared with MUT+ patients (36%). However, in the long-term follow-up (3–6 years), both groups presented with the same degree of clinical improvement (MUT−: 44% vs MUT+: 42%). Although the MUT+ group showed more severe axial signs preoperatively, MUT− patients developed levodopa– and deep brain stimulation–resistant axial signs within the first 3 to 6 years postoperatively, which diminished the initial benefit soon after surgery.
Conclusions: Patients with Parkin or PINK1 mutations benefit from subthalamic nucleus deep brain stimulation. However, the clinical response is not superior to non–mutation carriers and might be limited by more advanced axial motor symptoms at a relatively early disease stage.
Glossary
- DBS=
- deep brain stimulation;
- EOP=
- early-onset parkinsonism;
- H-Y=
- Hoehn and Yahr;
- LD=
- levodopa;
- LEDD=
- levodopa equivalent daily dose; meds ;
- MUT=
- mutation-positive patients;
- MUT=
- mutation-negative patients;
- NA=
- not available;
- NMF=
- no mutation found;
- PD=
- Parkinson disease;
- PIGD=
- postural instability/gait dysfunction;
- STN-DBS=
- subthalamic nucleus deep brain stimulation;
- UPDRS=
- Unified Parkinson’s Disease Rating Scale.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.